Accelerate Diagnostics Stock Price To Book

AXDX Stock

USD 1.10 0.06 5.17%

Accelerate Diagnostics fundamentals help investors to digest information that contributes to Accelerate Diagnostics' financial success or failures. It also enables traders to predict the movement of Accelerate Stock. The fundamental analysis module provides a way to measure Accelerate Diagnostics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Accelerate Diagnostics stock.

Other Current Liab Total Assets

Price To Book Ratio is likely to rise to -2.34 in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Accelerate Diagnostics Company Price To Book Analysis

Accelerate Diagnostics' Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.

P/B

MV Per Share

BV Per Share

More About Price To Book | All Equity Analysis

Accelerate Price To Book Driver Correlations

Understanding the fundamental principles of building solid financial models for Accelerate Diagnostics is extremely important. It helps to project a fair market value of Accelerate Stock properly, considering its historical fundamentals such as Price To Book. Since Accelerate Diagnostics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Accelerate Diagnostics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Accelerate Diagnostics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Common Stock	Current Deferred Revenue	Treasury Stock	Property Plant Equipment	Intangible Assets	Good Will	Short Term Debt	Net Tangible Assets	Long Term Debt	Short Term Investments	Capital Surpluse	Long Term Debt Total	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.43	0.08	-0.21	0.14	0.25	0.51	1.0	-0.57	-0.1	-0.32	0.5	-0.47	-0.54	-0.06	0.4	0.51	0.81	0.35	0.66	-0.05	0.42	0.37	0.17
Total Stockholder Equity	0.43		-0.82	0.55	-0.18	-0.51	-0.55	0.47	-0.12	-0.25	0.66	-0.27	-0.09	-0.13	-0.25	1.0	-0.52	0.4	-0.39	-0.05	-0.22	0.55	0.56	-0.01
Net Debt	0.08	-0.82		-0.66	0.14	0.69	0.84	0.03	-0.14	0.23	-0.83	0.5	-0.11	-0.09	0.19	-0.83	0.82	0.2	0.56	0.4	0.16	-0.27	-0.3	0.1
Retained Earnings	-0.21	0.55	-0.66		-0.8	-0.86	-0.66	-0.16	0.52	-0.69	0.9	-0.93	0.44	0.47	-0.39	0.58	-0.59	-0.07	-0.98	-0.74	-0.35	0.72	0.74	0.11
Accounts Payable	0.14	-0.18	0.14	-0.8		0.65	0.21	0.11	-0.55	0.75	-0.56	0.81	-0.45	-0.47	0.45	-0.21	0.12	-0.13	0.83	0.57	0.42	-0.76	-0.79	-0.25
Net Receivables	0.25	-0.51	0.69	-0.86	0.65		0.66	0.21	-0.31	0.66	-0.85	0.82	-0.29	-0.33	0.29	-0.53	0.62	0.19	0.84	0.62	0.26	-0.5	-0.53	-0.11
Total Liab	0.51	-0.55	0.84	-0.66	0.21	0.66		0.47	-0.38	0.05	-0.89	0.65	-0.32	-0.34	0.2	-0.57	0.95	0.38	0.62	0.62	0.18	-0.07	-0.14	0.25
Total Current Assets	1.0	0.47	0.03	-0.16	0.11	0.21	0.47		-0.56	-0.12	-0.28	0.46	-0.47	-0.52	-0.08	0.45	0.47	0.82	0.31	0.63	-0.07	0.45	0.4	0.16
Common Stock	-0.57	-0.12	-0.14	0.52	-0.55	-0.31	-0.38	-0.56		-0.3	0.42	-0.68	0.64	0.46	-0.14	-0.1	-0.34	-0.39	-0.62	-0.64	-0.13	0.21	0.23	0.02
Current Deferred Revenue	-0.1	-0.25	0.23	-0.69	0.75	0.66	0.05	-0.12	-0.3		-0.41	0.61	-0.3	-0.17	0.09	-0.27	0.08	-0.09	0.71	0.43	0.06	-0.76	-0.67	-0.57
Treasury Stock	-0.32	0.66	-0.83	0.9	-0.56	-0.85	-0.89	-0.28	0.42	-0.41		-0.84	0.36	0.38	-0.34	0.68	-0.83	-0.18	-0.85	-0.66	-0.31	0.44	0.49	-0.03
Property Plant Equipment	0.5	-0.27	0.5	-0.93	0.81	0.82	0.65	0.46	-0.68	0.61	-0.84		-0.56	-0.58	0.27	-0.31	0.61	0.28	0.98	0.86	0.25	-0.53	-0.54	-0.15
Intangible Assets	-0.47	-0.09	-0.11	0.44	-0.45	-0.29	-0.32	-0.47	0.64	-0.3	0.36	-0.56		0.56	-0.12	-0.05	-0.29	-0.31	-0.52	-0.53	-0.11	0.18	0.2	0.02
Good Will	-0.54	-0.13	-0.09	0.47	-0.47	-0.33	-0.34	-0.52	0.46	-0.17	0.38	-0.58	0.56		-0.13	-0.07	-0.3	-0.33	-0.54	-0.56	-0.11	0.19	0.2	0.02
Short Term Debt	-0.06	-0.25	0.19	-0.39	0.45	0.29	0.2	-0.08	-0.14	0.09	-0.34	0.27	-0.12	-0.13		-0.26	-0.09	-0.14	0.32	0.16	1.0	-0.35	-0.6	0.62
Net Tangible Assets	0.4	1.0	-0.83	0.58	-0.21	-0.53	-0.57	0.45	-0.1	-0.27	0.68	-0.31	-0.05	-0.07	-0.26		-0.54	0.38	-0.42	-0.08	-0.23	0.57	0.58	-0.01
Long Term Debt	0.51	-0.52	0.82	-0.59	0.12	0.62	0.95	0.47	-0.34	0.08	-0.83	0.61	-0.29	-0.3	-0.09	-0.54		0.4	0.57	0.58	-0.11	-0.02	-0.01	0.02
Short Term Investments	0.81	0.4	0.2	-0.07	-0.13	0.19	0.38	0.82	-0.39	-0.09	-0.18	0.28	-0.31	-0.33	-0.14	0.38	0.4		0.19	0.51	-0.13	0.54	0.5	0.14
Capital Surpluse	0.35	-0.39	0.56	-0.98	0.83	0.84	0.62	0.31	-0.62	0.71	-0.85	0.98	-0.52	-0.54	0.32	-0.42	0.57	0.19		0.82	0.29	-0.66	-0.67	-0.16
Long Term Debt Total	0.66	-0.05	0.4	-0.74	0.57	0.62	0.62	0.63	-0.64	0.43	-0.66	0.86	-0.53	-0.56	0.16	-0.08	0.58	0.51	0.82		0.14	-0.29	-0.3	-0.05
Short Long Term Debt	-0.05	-0.22	0.16	-0.35	0.42	0.26	0.18	-0.07	-0.13	0.06	-0.31	0.25	-0.11	-0.11	1.0	-0.23	-0.11	-0.13	0.29	0.14		-0.31	-0.57	0.64
Net Invested Capital	0.42	0.55	-0.27	0.72	-0.76	-0.5	-0.07	0.45	0.21	-0.76	0.44	-0.53	0.18	0.19	-0.35	0.57	-0.02	0.54	-0.66	-0.29	-0.31		0.96	0.31
Net Working Capital	0.37	0.56	-0.3	0.74	-0.79	-0.53	-0.14	0.4	0.23	-0.67	0.49	-0.54	0.2	0.2	-0.6	0.58	-0.01	0.5	-0.67	-0.3	-0.57	0.96		0.08
Capital Stock	0.17	-0.01	0.1	0.11	-0.25	-0.11	0.25	0.16	0.02	-0.57	-0.03	-0.15	0.02	0.02	0.62	-0.01	0.02	0.14	-0.16	-0.05	0.64	0.31	0.08

Click cells to compare fundamentals

Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.

Competition

Predict Accelerate Diagnostics

Price Book Value Ratio Over Time

Accelerate Book Value Per Share

Book Value Per Share

(1.51)

At this time, Accelerate Diagnostics' Book Value Per Share is fairly stable compared to the past year.

Based on the latest financial disclosure, Accelerate Diagnostics has a Price To Book of 0.0 times. This is 100.0% lower than that of the Life Sciences Tools & Services sector and 100.0% lower than that of the Health Care industry. The price to book for all United States stocks is 100.0% higher than that of the company.

Accelerate Price To Book Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Accelerate Diagnostics' direct or indirect competition against its Price To Book to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Accelerate Diagnostics could also be used in its relative valuation, which is a method of valuing Accelerate Diagnostics by comparing valuation metrics of similar companies.

Accelerate Diagnostics is currently under evaluation in price to book category among its peers.

Accelerate Fundamentals

	Return On Asset	-0.76
	Operating Margin	(2.88) %
	Current Valuation	65.61 M
	Shares Outstanding	25.04 M
	Shares Owned By Insiders	40.60 %
	Shares Owned By Institutions	17.45 %
	Number Of Shares Shorted	525.03 K
	Price To Earning	(15.18) X
	Price To Sales	2.19 X
	Revenue	12.06 M
	Gross Profit	3.3 M
	EBITDA	(49.77 M)
	Net Income	(61.62 M)
	Cash And Equivalents	36.77 M
	Cash Per Share	0.45 X
	Total Debt	39.22 M
	Debt To Equity	2.76 %
	Current Ratio	4.48 X
	Book Value Per Share	(1.36) X
	Cash Flow From Operations	(40.2 M)
	Short Ratio	7.77 X
	Earnings Per Share	(2.59) X
	Price To Earnings To Growth	(0.55) X
	Target Price	1.5
	Number Of Employees	134
	Beta	0.6
	Market Capitalization	26.8 M
	Total Asset	31.37 M
	Retained Earnings	(668.86 M)
	Working Capital	12.43 M
	Current Asset	91.68 M
	Current Liabilities	4.45 M
	Net Asset	31.37 M

About Accelerate Diagnostics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Accelerate Diagnostics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Accelerate Diagnostics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Accelerate Diagnostics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Accelerate Stock Analysis

When running Accelerate Diagnostics' price analysis, check to measure Accelerate Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Accelerate Diagnostics is operating at the current time. Most of Accelerate Diagnostics' value examination focuses on studying past and present price action to predict the probability of Accelerate Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Accelerate Diagnostics' price. Additionally, you may evaluate how the addition of Accelerate Diagnostics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC